Gilead Sciences Inc (GILD) Common Stock USD0.001

Sell:$96.90Buy:$96.94$0.97 (1.01%)

NASDAQ:0.25%
Market closed | Prices delayed by at least 15 minutes
Sell:$96.90
Buy:$96.94
Change:$0.97 (1.01%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$96.90
Buy:$96.94
Change:$0.97 (1.01%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Key people

Daniel P O'Day
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer
Deborah H. Telman
Executive Vice President - Corporate Affairs, General Counsel
Dietmar P. Berger
Chief Medical Officer
Johanna Mercier
Chief Commercial Officer
Anthony Welters
Lead Independent Director
Ted W. Love
Director
Jacqueline K. Barton
Independent Director
Jeffrey A. Bluestone
Independent Director
Sandra J. Horning
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US3755581036
  • Market cap
    $116.96bn
  • Employees
    18,000
  • Shares in issue
    1.25bn
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.